Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-26-003819
Filing Date
2026-05-13
Accepted
2026-05-13 16:18:43
Documents
61
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR MAR 2026 sunshine_i10q-033126.htm   iXBRL 10-Q 587236
2 CERTIFICATION sunshine_ex3101.htm EX-31.1 13507
3 CERTIFICATION sunshine_ex3102.htm EX-31.2 13492
4 CERTIFICATION sunshine_ex3201.htm EX-32.1 5735
10 GRAPHIC logo.jpg GRAPHIC 8485
  Complete submission text file 0001683168-26-003819.txt   3367325

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sbfm-20260331.xsd EX-101.SCH 29914
6 XBRL CALCULATION FILE sbfm-20260331_cal.xml EX-101.CAL 45925
7 XBRL DEFINITION FILE sbfm-20260331_def.xml EX-101.DEF 114780
8 XBRL LABEL FILE sbfm-20260331_lab.xml EX-101.LAB 252901
9 XBRL PRESENTATION FILE sbfm-20260331_pre.xml EX-101.PRE 214090
65 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_i10q-033126_htm.xml XML 331923
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-330-0684
Sunshine Biopharma Inc. (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41282 | Film No.: 26973589
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)